<table>
<thead>
<tr>
<th>Policy Title</th>
<th>Policy Number</th>
<th>Last Revised</th>
</tr>
</thead>
<tbody>
<tr>
<td>PancraGEN™ Molecular Diagnostic Test for Evaluation of Pancreatic Cists</td>
<td>603</td>
<td>01/24/17</td>
</tr>
</tbody>
</table>
MEDICAL POLICY

PANCRAGEN™ MOLECULAR DIAGNOSTIC TEST FOR EVALUATION OF PANCREATIC CYSTS

Policy # 603
Implementation Date: 11/29/16
Review Dates: 12/21/17, 12/4/18, 12/16/19
Revision Dates: 1/24/17

Description
Pancreatic cysts may be detected in over 2% of patients who undergo abdominal imaging for unrelated reasons, and this frequency increases with age.

Most pancreatic cystic neoplasms (PCNs) are detected incidentally when abdominal imaging is performed for other indications. PCNs account for more than 50% of pancreatic cysts, even in patients with a history of pancreatitis. The first step in evaluating a cyst is to obtain magnetic resonance imaging (MRI) with magnetic resonance cholangiopancreatography (MRCP). Cross-sectional imaging is obtained to determine if there are features present that can identify the specific cyst type and to determine if there are any findings that increase the risk of malignancy (large cyst > 3 cm, a solid component within the cyst, main pancreatic duct dilation). Endoscopic ultrasound with fine-needle aspiration (EUS-FNA) provides high-quality imaging of the pancreas and the opportunity to sample pancreatic lesions, which increases diagnostic accuracy. The addition of intraductal EUS may also increase diagnostic accuracy but is not part of the routine evaluation of pancreatic cysts.

Once a cyst has been aspirated, it undergoes analysis of any fluid obtained. This includes cytology, CEA level, and amylase along with genetic testing for KRAS, GNAS, and sometimes other markers. In some instances, these markers are indeterminate and a decision to either monitor the cyst with periodic imaging based on established guidelines, or surgical intervention, must be undertaken with less certainty as to the true necessity of this invasive intervention.

PancraGEN™ (Interpace Diagnostics LLC, Parsippany, NJ), formerly Pathfinder TG (RedPath Diagnostics) is a laboratory test that integrates cytological, fluid chemistry (CEA, amylase), imaging, and DNA analysis into 4 diagnostic categories that works to stratify the risk of malignancy, particularly in cysts with indeterminate features. On a DNA level, PancraGEN measures the quantity, quality, and level of DNA damage (specifically, the presence and clonality of loss of heterozygosity mutations (LOH) next to tumor suppressor genes and oncogene point mutations) that is causally responsible for pancreatic cancer. PancraGEN measures 15 genetic markers which are distributed across 10 chromosomal regions including KRAS and GNAS.

Cyst fluid chemistry (i.e., CEA, amylase), imaging, levels of atypia, and cellularity are abstracted from the patients’ records provided by the managing physician. Parameters of these initial tests are used along with the results of DNA analysis to compute a malignancy risk estimate in an attempt to help guide surgery.

Commercial Plan Policy

SelectHealth does NOT cover PancraGEN molecular diagnostic test for evaluation of pancreatic cysts as it is considered unproven.
Pathology Policies, Continued

PancraGEN™ Molecular Diagnostic Test for Evaluation of Pancreatic Cysts, continued

SelectHealth Advantage (Medicare/CMS) (Preauthorization Required)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the SelectHealth Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp or the manual website.

SelectHealth Community Care (Medicaid/CHIP) (Preauthorization Required)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the SelectHealth Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website http://health.utah.gov/medicaid/manuals/directory.php or the Utah Medicaid code Look-Up tool.

Summary of Medical Information

Two systematic reviews and 14 primary studies were identified that met inclusion criteria for this review. Data on > 1,500 samples have been reported in the literature since 2006. The majority of the literature on PancraGEN or Pathfinder (as this test was previously known) was related to the clinical validity of the test, namely, the test’s ability to accurately profile tissue samples versus cytology, cyst fluid, or other standard means of cyst assessment. All the studies that noted sensitivity and specificity showed that the test has higher of the latter than the former with specificities ranging from 75% to 100%. Of the 14 primary studies, only 1 paper (Das et al.) discussed the health economics of the test and identified the noteworthy number needed to treat of 56. Similarly, only 2 papers (Kowalski and Loren et al.) discussed the potential clinical utility of the study showing that use of the test may improve patient surveillance.

In general, the literature shows some measure of clinical validity but fails to prove the clinical utility of the test (e.g., altering treatment plans, improving morbidity and mortality, improving progression-free survival, etc.). Given that the test has an average specificity of 88%, the lack of clinical utility data, limited follow-up periods in the literature, and evidence of improved outcomes resulting from use of PancraGEN, the current body of evidence is not sufficient to draw meaningful conclusions regarding the clinical usefulness of the test.

Billing/Coding Information

CPT CODES

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81479</td>
<td>Unlisted molecular pathology procedure</td>
</tr>
<tr>
<td>84999</td>
<td>Unlisted chemistry procedure</td>
</tr>
</tbody>
</table>

HCPCS CODES

No specific codes identified

Key References

1. Interpace Diagnostics LLC. Value Dossier - PancraGEN. 2016 [cited 2016 January 28].
13. ECRI. PancraGEN (Interpace Diagnostics, LLC) for Assessing Cysts to Determine Risk for Pancreatic Cancer. 2016 [cited 2016 March].

Disclaimer
This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract for member coverage or reimbursement policy. SelectHealth may make no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. SelectHealth reserves the right to amend these policies without notice to healthcare providers or the member.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically.

© 2020 SelectHealth. All rights reserved. 1196662 01/21

© CPT Only – American Medical Association